SITC Resource Library

On April 5, 2024, the Society for Immunotherapy of Cancer (SITC) held the IO Surrogate Endpoints Virtual Summit. The edited recording of the Summit along with the full presentation slide deck are available below. 

Program Information

Immunotherapy as a modality has grown significantly in recent years, primarily due to the number of therapies being approved via the FDA’s accelerated approval program. These approvals are often facilitated through the use of endpoints that can serve as surrogates for “gold standard” clinical trial metrics such as overall survival. Surrogate endpoints for IO clinical trials have been of significant interest recently for various reasons. The discovery of effective novel surrogate endpoints is critical to increase the quality, quantity, and speed at which novel therapies can gain accelerated approval through clinical trials. As such, the SITC Biomarkers Committee and Regulatory Subcommittee felt that a summit on this topic would be both timely and impactful for advancing the field of immunotherapy. (All times are listed in Eastern Time):

• 9:30-9:45am - Welcome and Setting the Stage​

• 9:45-10:00am - IO Endpoints Presentation​

• 10:00-10:30am - Open Discussion​

• 10:30-10:45am - Deep Response Rate + Remission/Cure Rate Presentation​

• 10:45-11:15am - Open Discussion​

• 11:15-11:30am - Pathologic Evaluation Presentation​

• 11:30-12:00pm - Open Discussion​

• 12:00-12:30pm - Lunch Break​

• 12:30-12:45pm - Role of ctDNA Presentation​

• 12:45-1:15pm - Open Discussion​

• 1:15-1:30pm - Role of Imaging Presentation​

• 1:00-2:00pm - Open Discussion​

• 2:00-2:30pm - General Discussion, Output Development, and Future Directions